Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials
- 3 February 2014
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 15 (6), 749-766
- https://doi.org/10.1517/14656566.2014.887680
Abstract
Objective: To evaluate long-term safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes as monotherapy or in combination with other oral antidiabetic agents, we conducted 52-week, open-label, randomized controlled trials. Research design and methods: The single-agent trial included patients with inadequate glycemic control on diet and exercise, whereas the add-on trial included those uncontrolled with any of the oral antidiabetic agents. In both trials, patients were randomly assigned to receive tofogliflozin 20 or 40 mg once daily orally for 52 weeks. Main outcome measures: Safety assessments. Results: A total of 194 patients (65, 20-mg group; 129, 40-mg group) were enrolled into the single-agent trial, whereas 602 (178 and 424, respectively) were enrolled into the add-on trial. Tofogliflozin was well tolerated for 52 weeks in both trials with < 6% of treatment discontinuation because of adverse events in each treatment group. It also reduced hemoglobin A1c. In the single-agent trial, mean reductions at 52 weeks were 0.67 and 0.66% in the 20- and 40-mg groups, respectively. In the add-on trial, mean reductions ranged from 0.71 to 0.93% across the subgroups by dose and background therapy. Conclusion: Tofogliflozin was well tolerated and showed sustained efficacy in both trials.Keywords
This publication has 16 references indexed in Scilit:
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of InsulinAnnals of Internal Medicine, 2012
- Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and MiceJournal of Pharmacology and Experimental Therapeutics, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulinDiabetes, Obesity and Metabolism, 2012
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and ExerciseDiabetes Care, 2010
- Consequences of Delaying Progression to Optimal Therapy in Patients with Type 2 Diabetes Not Achieving Glycemic GoalsSouthern Medical Journal, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Active sugar transport in health and diseaseJournal of Internal Medicine, 2007
- The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.JCI Insight, 1994